CYTHIOATE

Chemistry - Cythioate is an oral organophosphate agent.

Storage, Stability, Compatibility

Unless otherwise noted by the manufacturer store products intight, light resistant containers at room temperature.

Pharmacology - CYTHIOATE

After being distributed into body fluids, cythioate is ingested by fleas, ticks anddemodectic mites. It then inhibits acetylcholinesterase thereby interfering with neuromusculartransmission.
Uses, Indications - Cythioate is approved for use for flea control in dogs of all ages. It may also beuseful in treating tick infestations and the control od demodectic mites.

Pharmacokinetics - CYTHIOATE

No information located.

Contraindications, Precautions, Reproductive Safety

Cythioate is contraindicated in grey-hounds (no information located on safety in other sight hound breeds). It is also contraindicated insick, debilitated, stressed (recovering from surgery, etc.), anemic or pregnant animals.

Adverse Effects, Warnings

Cythioate is relatively safe and at recommended doses should bedevoid of adverse effects in otherwise healthy dogs. At higher doses and in susceptible dogs, muscle tremors and hyperexcitability may be noted.
Repeated or prolonged dosing may lead to adverse effects. The manufacturer warns against usingcythioate simultaneously with other drugs, insecticides, pesticides or chemicals havingcholinesterase inhibiting activity and using within a few days before or after using any othercholinesterase inhibitor.

Overdosage, Acute Toxicity

If overdoses occur, vomiting, tremors, hyperexcitability, salivationand diarrhea may occur. The manufacturer recommends treating with atropine at 0.22 mg/kg IM at15-30 minute intervals depending upon the severity of the symptoms. Use of succinylcholine, theophylline/aminophylline, reserpine, and respiratory depressant drugs (e.g., narcotics, phenothiazines) should be avoided in patients with organophosphate toxicity. If an ingestion occursby a human, contact a poison control center, physician or hospital emergency room.

Drug Interactions

Acepromazine or other phenothiazines should not be given within onemonth of worming with an organophosphate agent as their effects may be potentiated. Because ofits anticholinesterase activity, avoid the use of organophosphates with DMSO. Cythioate couldtheoretically enhance the toxic effects of levamisole. Pyrantel Pamoate (or tartrate) adverseeffects could be intensified if used concomitantly with an organophosphate. Patients receivingorganophosphate anthelmintics should not receive succinylcholine or other depolarizing musclerelaxants for at least 48 hours. Drugs such as morphine, neostigmine, physostigmine andpyridostigmine should be avoided when using organophosphates as they can inhibitcholinesterase.